At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Cabozantinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma
In Brief
A Phase 2 clinical trial evaluating Cabozantinib, Pharmacogenomic Study, and 1 other intervention for Metastatic Carcinoma in the Adrenal Cortex and 3 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartFeb 2018
Primary CompletionJan 2024
TodayJul 2026
First PostedDec 12, 2017
Enrollment StartFeb 26, 2018
Primary CompletionJan 12, 2024
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 8.6 years ago
Interventions
Cabozantinibdrug
Given PO
Pharmacogenomic Studyother
Correlative studies
Pharmacokinetic Studyother
Correlative studies